Predicted levels of HIV drug resistance: potential impact of expanding diagnosis, retention, and eligibility criteria for antiretroviral therapy initiation.
BACKGROUND
There is concern that the expansion of antiretroviral roll-out may impact future drug resistance levels and hence compromise the benefits of antiretroviral therapy (ART) at an individual and population level. We aimed to predict future drug resistance in South Africa and its long-term effects.


METHODS
The previously validated HIV Synthesis model was calibrated to South Africa. Resistance was modeled at the level of single mutations, transmission potential, persistence, and effect on drug activity.


RESULTS
We estimate 652 000 people (90% uncertainty range: 543 000-744 000) are living with nonnucleoside reverse transcriptase inhibitor (NNRTIs)-resistant virus in South Africa, 275 000 in majority virus [Non-nucleoside reverse transcriptase inhibitor resistant virus present in majority virus (NRMV)] with an unsuppressed viral load. If current diagnosis and retention in care and eligibility criteria are maintained, in 20 years' time HIV incidence is projected to have declined by 22% (95% confidence interval, CI -23 to -21%), and the number of people carrying NNRTI resistance to be 2.9-fold higher. If enhancements in diagnosis and retention in care occur, and ART is initiated at CD4 cell count less than 500  cells/μl, HIV incidence is projected to decline by 36% (95% CI: -37 to -36%) and the number of people with NNRTI resistance to be 4.1-fold higher than currently. Prevalence of people with viral load more than 500  copies/ml carrying NRMV is not projected to differ markedly according to future ART initiation policy, given the current level of diagnosis and retention are maintained.


CONCLUSIONS
Prevalence of resistance is projected to increase substantially. However, introduction of policies to increase ART coverage is not expected to lead to appreciably higher prevalence of HIV-positive people with resistance and viral load more than 500  copies/ml. Concern over resistance should not stop expansion of treatment availability.
aResearch Department of Infection & Population Health, UCL, London, UK bWorld Health Organization, Geneva, Switzerland cTufts University School of Medicine, Boston, Massachusetts, USA dDepartment of Infection, University College London, London, UK eDepartment of Medicine, University of the Witwatersrand, Johannesburg, South Africa fDepartment of Infectious Disease, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Valentina
V
Cambiano
Silvia
S
Bertagnolio
Michael R
MR
Jordan
Deenan
D
Pillay
Joseph H
JH
Perriëns
Francois
F
Venter
Jens
J
Lundgren
Andrew
A
Phillips
D000293:Adolescent; D000328:Adult; D000368:Aged; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D024882:Drug Resistance, Viral; D004363:Drug Utilization / Q000706:statistics & numerical data*; D005260:Female; D015658:HIV Infections / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology / Q000821:virology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008962:Models, Theoretical; D015995:Prevalence; D013019:South Africa / Q000453:epidemiology; D055815:Young Adult
D044966:Anti-Retroviral Agents